Navigation Links
Vasogen Announces Sale of Patent Application and Provides Corporate Update
Date:2/2/2009

MISSISSAUGA, ON, Feb. 2 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN; TSX:VAS) today announced that it has sold a United States patent application and its related foreign counterparts for US$400,000. This device-based intellectual property has not been used to date in the Celacade System; however, Vasogen has retained rights to this technology for any potential use as it relates to its Celacade System.

The Company today also announced that it continues to advance the process associated with its ongoing strategic review and expects to be in a position to provide a further update to shareholders over the coming weeks. As previously announced, Vasogen has been reviewing various strategic alternatives for the purpose of enhancing shareholder value.

Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to complete a sale, merger, acquisition, or other strategic alternative, statements regarding the status of development, or expenditures relating to the Celacade(TM) System or our VP series of drugs including VP015 and VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You s
'/>"/>

SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
2. Vasogen Provides Corporate Update
3. Vasogen Announces Third Quarter 2008 Results
4. Vasogen Announces Second Quarter 2008 Results
5. Vasogen Provides Corporate Update
6. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
8. Vasogen Announces Implementation of Strategic Restructuring Plan
9. Vasogen Announces First Quarter 2008 Results
10. Vasogen to Webcast its Annual Meeting
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Cellectis therapeutics, a subsidiary of Cellectis (Alternext: ALCLS) ... genome engineering, today announced the appointment of Dr. ... Dr. Scharenberg is an attending physician ... of Pediatrics and Immunology at the University of ...
... Pharma, Inc. is pleased to announce that it has ... its lead drug for the treatment of stroke and ... A Phase 1, Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single ... of Oral and Intravenous Administration of Methamphetamine Hydrochloride in ...
... For most people, the clock changes just twice a year ... Disorder (N24HWD, or Non-24), their internal body clock changes ... it is estimated that approximately 65,000 – 95,000 people suffer ... period can advance by about 15 minutes each night. Patients ...
Cached Biology Technology:Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics 2Sinapis Pharma Completes Phase I Trial 2New Website Targets Common Sleep Disorder in Blind Individuals 2
(Date:4/22/2014)... April 22, 2014 Scientists from the Florida campus ... protein complex that plays a critical but previously unknown ... study, which showed a novel role for a protein ... the journal eLife , a publisher supported by ... and the Wellcome Trust. , "This is a critical ...
(Date:4/22/2014)... PETA International Science Consortium Ltd.,s nanotechnology expert will present ... nanomaterial hazard assessment" at the 7th International Nanotoxicology ... Antalya, Turkey. , Dr. Monita Sharma will outline ... US National Academy of Sciences, " Toxicity Testing in ... which recommends use of non-animal methods involving human cells ...
(Date:4/22/2014)... American Societies for Experimental Biology (FASEB) has released ... how funding from the National Institutes of Health (NIH) ... Rico. "FASEB is pleased to make these factsheets available ... NIH to their state," said FASEB President, Margaret K. ... for biomedical research funding, investing $29.2 billion in ...
Breaking Biology News(10 mins):Scientists identify critical new protein complex involved in learning and memory 2
... McGill University,s upcoming Conference on Global Food Security (Sept. ... in key organizations around the world to discuss solutions ... radar screens, but which has not gone away. ... own hemisphere, where Haiti has been hammered by hurricanes ...
... and economics will join forces at the University of ... also host an exhibition of some of the region,s ... and the environment. Today,s event will also see ... and the Environment (I-SEE) by David Willetts MP, Shadow ...
... immune-defense cells influenced by embryonic stem cell-derived cells can ... all without the use of immunosuppressive drugs. The ... (VA) Medical Center finding has implications for possible improvements ... study results appeared Friday in the online journal ...
Cached Biology News:McGill conference on Global Food Crisis draws impressive list of international participants 2McGill conference on Global Food Crisis draws impressive list of international participants 3University to showcase cutting edge environmental research 2Embryonic stem cells might help reduce transplantation rejection 2
...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
...
... SureLINK HRP Conjugation Kits are based ... conjugates that are consistent and reproducible. ... to conjugate your protein or antibody, ... storage buffer. Activated HRP is ...
Biology Products: